Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Bristol-Myers Squibb: Avoid This Short-Term Laggard
Seeking Alpha
Saturday, August 11, 2012 - 12:05pm
tags:
Bristol-Myers Squibb
Eli Lilly And Stock To Go Ex-dividend Monday (LLY)
The Street
Saturday, August 11, 2012 - 12:01pm
tags:
Eli Lilly
Strong But Vulnerable
Motley Fool
Saturday, August 11, 2012 - 12:01pm
tags:
Abbott
Stem Cell Therapy Gaining Ground And Investor Attention
Seeking Alpha
Saturday, August 11, 2012 - 11:43am
tags:
stem cells, Osiris Therapeutics, Aastrom Biosciences, NeoStem, Baxter International
Acadia Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Seeking Alpha
Saturday, August 11, 2012 - 11:34am
tags:
Acadia, earnings
ViroPharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Seeking Alpha
Saturday, August 11, 2012 - 11:31am
tags:
ViroPharma, earnings
3 Reasons This Speculative Bio-Pharma Is A Winner
Seeking Alpha
Saturday, August 11, 2012 - 11:30am
tags:
MannKind, Afrezza, diabetes, type 1 diabetes, type 2 diabetes
Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Laggard
The Street
Saturday, August 11, 2012 - 11:28am
tags:
Arena Pharmaceuticals
BioMarin Pharmaceuticals Inc: Today's Featured Health Care Laggard
The Street
Saturday, August 11, 2012 - 11:26am
tags:
Biomarin
Codexis Drops After Saying Shell Won't Continue To Fund
Bloomberg
Saturday, August 11, 2012 - 11:25am
tags:
Codexis
Halozyme Momentum Expected To Continue
Yahoo/Reuters
Saturday, August 11, 2012 - 11:24am
tags:
Halozyme
Healthcare Review: PharmAthene & Codexis Slump On News, Amicus Rises
Yahoo/Reuters
Saturday, August 11, 2012 - 11:23am
tags:
PharmAthene, Codexis, Arena Pharmaceuticals, Pfizer, Amicus Therapeutics, Celldex
Arena Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Seeking Alpha
Saturday, August 11, 2012 - 11:22am
tags:
Arena, earnings
How Much Can Vivus, Arena Pharma Charge for Diet Pills?
Minyanville
Saturday, August 11, 2012 - 11:21am
tags:
Vivus, Arena Pharmaceuticals, obesity, weight loss, Qsymia, Belviq
Is the Price Finally Right to Buy InterMune?
Motley Fool
Saturday, August 11, 2012 - 11:19am
tags:
InterMune
Merrimack 2Q loss narrows on drug payments
Yahoo/AP
Saturday, August 11, 2012 - 11:18am
tags:
Merrimack Pharmaceuticals, earnings
How Much Can Vivus, Arena Pharma Charge for Diet Pills?
Minyanville
Friday, August 10, 2012 - 6:38pm
tags:
Vivus, Arena Pharmaceuticals, obesity, Belviq, Qsymia
Mylan receives OK to sell generic Provigil doses
Yahoo/AP
Friday, August 10, 2012 - 6:37pm
tags:
Mylan, Provigil, generics
Biodel's CEO Discusses F3Q12 Results - Earnings Call Transcript
Seeking Alpha
Friday, August 10, 2012 - 6:34pm
tags:
Biodel, earnings
Alexion's Soliris to Merck's Januvia, top 20 generate huge growth
Fierce Pharma
Friday, August 10, 2012 - 6:31pm
tags:
Merck, Alexion, Soliris, Januvia

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.